CD19-directed engineered T cells expressing a chimeric antigen receptor (CAR-T) was also considered as an effective treatment for CNS relapse of ALL [8], but the patient refused the treatment option for financial reasons. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.